Metformin Improves Ileal Epithelial Barrier Function in Interleukin-10 Deficient Mice

Area of Science:

• Gastroenterology
• Cell Biology
• Pharmacology

Background:

• Intestinal epithelial barrier impairment is central to inflammatory bowel disease (IBD).
• Proper intestinal epithelial cell proliferation and differentiation are vital for maintaining gut integrity.
• Metformin, a common anti-diabetic drug, is investigated for its potential protective effects on the gut.

Purpose of the Study:

• To evaluate the protective effects of metformin on ileal epithelial barrier integrity in interleukin-10 deficient (IL10KO) mice, an IBD model.
• To elucidate the role of AMP-activated protein kinase (AMPK) in metformin's effects on gut epithelial cells.

Main Methods:

• Wild-type and IL10KO mice were treated with or without metformin for 6 weeks.
• Ileum tissues were analyzed for epithelial cell proliferation, differentiation, and barrier function.
• In vitro studies using Caco-2 cells and gain/loss of function assays examined the role of AMPK.

Main Results:

• Metformin mitigated increased intestinal cell proliferation and restored the villus/crypt ratio in IL10KO mice.
• Metformin enhanced goblet and Paneth cell differentiation and improved ileal barrier function.
• Metformin activated AMPK, increased differentiation regulator mRNA levels, and suppressed macrophage pro-inflammatory activity in IL10KO mice.

Conclusions:

• Metformin supplementation promotes secretory cell differentiation and improves epithelial barrier function in IL10KO mice.
• AMPK activation is likely a key mechanism mediating metformin's beneficial effects on the gut epithelium.
• Metformin demonstrates significant therapeutic potential for gut epithelial health in IBD.